Expected Moves

Shenzhen Neptunus is expected to release its Q2 2026 financial results, the first interim print since receiving the ST (Special Treatment) designation due to the adverse internal control audit.

Regulatory deadline for the company to provide a detailed progress report on rectifying the 1.29 billion RMB external financial assistance and guarantee deficiencies that led to its ST label.

Release of the third-quarter financial results, highlighting ongoing debt service capabilities and Q3 operating margins amid deep corporate restructuring.

Anticipated deadline for major creditors to agree on a debt forbearance or restructuring framework ahead of the critical FY2026 annual audit.

Speculative window for a local state-owned enterprise (SOE) or government proxy to announce a capital injection or asset reorganization to save the regional pharmaceutical distributor.

The definitive catalyst for ST Neptunus: the release of FY2026 audited financials and the internal control auditor's opinion, which will determine if the delisting risk warning is removed or escalated.